Inhibrx CEO and leadership

Brendan is a co-founder of Inhibrx and serves as its Chief Operating Officer and VP of Biotherapeutics. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporation strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine

Quinn leads the target identification, validation and therapeutic lead selection and oversees the development strategy for Inhibrx’s biotherapeutic pipeline. Prior to founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Quinn lead groups of Ph.D./M.D. level investigators in the conception and development of novel target identification and validation platforms. Quinn lead the first therapeutic antibody from GNF to transition from bench-top to clinical trials. His research on cell death at the Stanford-Burnham-Prebys Medical Discovery Institute was highly cited. Quinn received his Ph.D. in biochemistry from the University of Utah School of Medicine.

Brendan is a co-founder of Inhibrx and serves as its Chief Operating Officer and VP of Biotherapeutics. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporation strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine

Quinn leads the target identification, validation and therapeutic lead selection and oversees the development strategy for Inhibrx’s biotherapeutic pipeline. Prior to founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Quinn lead groups of Ph.D./M.D. level investigators in the conception and development of novel target identification and validation platforms. Quinn lead the first therapeutic antibody from GNF to transition from bench-top to clinical trials. His research on cell death at the Stanford-Burnham-Prebys Medical Discovery Institute was highly cited. Quinn received his Ph.D. in biochemistry from the University of Utah School of Medicine.